Company / Net Income
United Therapeutics Net Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
$1.3B
FY2025
5-year range
$475.8M / $1.3B
FY2021-FY2025
Trend
+11.7%
vs FY2024
Sector context
#15 of 216
Health Care
What the data says
Among 216 Health Care companies, United Therapeutics is in the top 7% for net income. Net Income has increased for 5 consecutive years, from -$105M in FY2019 to $1.3B in FY2025.
Based on SEC 10-K filings.
$1.3B in FY2025 with a 3-year CAGR of +22.4%. Top quartile in the Health Care sector.
Improved from $985M to $1.3B over the past 2 years.
Health Care sector context is included.
Net Income over time
Growth rates
- 3-Year CAGR
- +22.4%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 7% in Health CareTop 7% of 216This company $1.3B Sector average $454.3M
▼
+193.8% above sector average
Key checks
Key Insights
- United Therapeutics's net income has grown for 4 consecutive years.
- 3-year CAGR of +22.4%, indicating consistent growth.
- In FY2025, net income increased 11.7% year-over-year.
- Ranks #15 out of 216 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 6.00 (safe zone, above 2.9 threshold)
- Strong profit margin: 40.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.3B | +11.7% |
| FY2024 | $1.2B | +21.4% |
| FY2023 | $984.8M | +35.4% |
| FY2022 | $727.3M | +52.9% |
| FY2021 | $475.8M | - |
| FY2020 | - | - |
| FY2019 | -$104.5M | -117.7% |
| FY2018 | $589.2M | -9.6% |
| FY2017 | $651.6M | -8.7% |
| FY2016 | $713.7M | +9.5% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026